Generate Biomedicines News and Activities
Presence
Generate Biomedicines develops new medicines using machine learning and biology. It provides protein therapeutics, drug discovery services, and development programs for patients, healthcare partners, and pharmaceutical companies.
Generate Biomedicines products and services overview:
- Protein therapeutics
- Antibody medicines
- Drug discovery
- AI drug design
- Research partnerships
- Clinical development
Revenue: ~$0 million
Employees: 400
Headquarters: Somerville, United States (USA)
Generate Biomedicines is one of the...
Acquisition, funding and merger involving Generate Biomedicines.
- Generate Biomedicines is now listed under ticker GENB. (posted on February 27 2026).
Executives
View the org chart displaying its 21 main executives
Most searched biographies at Generate Biomedicines
- Michael Nally, Chief Executive Officer and Director
- Nancy Simonian, Director
- Daria Hazuda, Senior Vice President, Discovery Strategy
Popular executive movements at Generate Biomedicines
- Aarif Khakoo has joined the company as Chief Scientific Officer (posted on February 27 2026).
Create your alert
to follow the executive moves at Generate Biomedicines.
Pharmaceuticals
Generate Biomedicines has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Corden Pharma has announced the acquisition of AmbioPharm (posted on June 5 2026).
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Generate Biomedicines
- Pharma’s AI Investment Signals New Drug Discovery Paradigm
- PharmaVoice’s Crystal Ball: What’s next for AI and drug R&D
- Q&A: Long-acting anti-TSLP antibody for severe asthma moves into phase 3
- Generate to launch Phase 3 TSLP drug studies, as AI bio enters its clinical era
- Monoclonal antibody effects persist for 6 months in patients
- Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox
- Is there a market for new COVID-19 drugs?
- Meet Nvidia CEO Jensen Huang, the man behind the company powering today's artificial intelligence
- Media Center
- Unlocking Molecular Mysteries: Ed Brignole on CryoEM's Role in Drug…
- View more press releases Close
Social media about Generate Biomedicines
- Generate Biomedicines on Wikipedia, Google News & Yahoo Finance
- Generate Biomedicines on LinkedIn, X (Twitter) & YouTube
